Navigation Links
ViroPharma to Participate in Two June Healthcare Investor Conferences
Date:6/3/2010

EXTON, Pa., June 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Jefferies 2010 Global Life Sciences Conference at 4:00 P.M. ET on Wednesday, June 9, 2010.  The conference is being held at the Grand Hyatt in New York City.

Mr. Roberts also will present at the ThinkEquity Healthcare Conference at 1:30 P.M. ET on Wednesday, June 16, 2010.  The conference is being held at the Princeton Club in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma To Host Investor Day
2. ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
4. Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
5. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
6. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
7. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
11. ViroPharma Announces Discontinuation of HCV-796 Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), ... Michigan residents. Naloxone is available ... retail pharmacy, G-3320 Beecher Road. ... and Drug Administration, is intended to block or reverse ... and loss of consciousness. The medication is often carried ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... DUBLIN, Aug. 8, 2017   ... $3.12 diluted (GAAP) loss per share from continuing operations ... Products revenues increased 16 percent to $110 million ... increased 27 percent to $161 million ... (EPS) from continuing operations increased 8 percent to $0.93 ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon ... all over the country. , Outdoor running increases exposure to ultraviolet radiation, a ... increased risk of melanoma, and only half may be adequately protecting themselves with ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... San Diego ... ) health care reform plan, has announced his candidacy for the 52nd Congressional District ... and shared in America’s Promise. Coming to this country at age eleven after suffering ...
(Date:8/20/2017)... ... ... State Farm Neighborhood Assist® has named The Southern Maryland Team Anti-Bullying Program ... initiative wins, Gals Lead – Dream Queen Foundation’s signature teen girl program to help ... Calvert and Charles Counties. The program could potentially impact nearly 17,500 female students (49.4 ...
(Date:8/19/2017)... MD (PRWEB) , ... August 18, 2017 , ... ... and Drug Administration Reauthorization Act of 2017, legislation that provides for greater public ... mild to moderate hearing loss to access OTC hearing aids without being seen ...
(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, an assisted ... passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading the way ... time to refresh the carpeting with the goal of maintaining the same precise ...
Breaking Medicine News(10 mins):